Invicta Diagnostic IPO Details: Price, Dates & Financials
The Invicta Diagnostic IPO GMP strength score is 7.7 out of 10, which the dashboard rates as Good. The Invicta Diagnostic IPO valuation is tagged Strong. The Invicta Diagnostic IPO QIB category is reserved for 40.28% of the offer. The Invicta Diagnostic IPO NII/HNI category is reserved for 16.39% of the offer. The Invicta Diagnostic IPO Retail (RII) category is reserved for 38.3% of the offer. Live subscription numbers for the Invicta Diagnostic IPO are not yet available, and amounts are calculated at the upper price band of ₹85.
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | — | 1,332,800 (40%) | — |
| NII / HNI | — | 542,400 (16%) | — |
| Retail (RII) | — | 1,267,200 (38%) | — |
| Market Maker | — | 166,400 (5%) | — |
| Total | — | 3,308,800 (100%) | — |
* Amount calculated at upper price band (₹85) · ** Total includes all investor categories
- 1 Initiation of Refund 05 Dec 2025
- 2 Credit of Shares to Demat 05 Dec 2025
- Retail allocation is good at 38% of the total offering.
- HNI/NII demand is good at 16%.
- Institutional (QIB) interest is strong at 40%.
- The IPO P/E of 13x reflects a strong valuation relative to typical market ranges.
- Pre-issue EPS of ₹6 compares to post-issue EPS of ₹7 after dilution.
This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.
GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.